Literature DB >> 20108343

Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex.

Joseph G Pressey1, Jordan M Wright, James I Geller, David B Joseph, Christine S Pressey, David R Kelly.   

Abstract

A male with tuberous sclerosis complex (TSC) developed a chest wall fibromatosis and bilateral multifocal renal cell carcinoma (RCC). The fibromatosis tumor was initially resected during infancy but recurred 5 years later. At that time, bilateral RCC was also detected, leading to the resection of the more extensively affected right kidney. In an attempt to avoid bilateral nephrectomies, the patient was treated with the mTOR inhibitor sirolimus. Within 6 months of therapy, the fibromatosis and remaining RCC tumors responded substantially with minimal adverse effects. Copyright 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20108343     DOI: 10.1002/pbc.22401

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  13 in total

1.  Therapeutic targeting of cancers with loss of PTEN function.

Authors:  Lloye M Dillon; Todd W Miller
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

Review 2.  [Mesenchymal abdominal tumors in children].

Authors:  G A Krombach
Journal:  Radiologe       Date:  2018-01       Impact factor: 0.635

Review 3.  Advances in therapy for pediatric sarcomas.

Authors:  Aaron Weiss; Jonathan Gill; John Goldberg; Joanne Lagmay; Holly Spraker-Perlman; Rajkumar Venkatramani; Damon Reed
Journal:  Curr Oncol Rep       Date:  2014       Impact factor: 5.075

Review 4.  Rapamycin and rapalogs for tuberous sclerosis complex.

Authors:  Teguh H Sasongko; Nur Farrah Dila Ismail; Zamh Zabidi-Hussin
Journal:  Cochrane Database Syst Rev       Date:  2016-07-13

5.  The use of everolimus to target carcinogenic pathways in a patient with renal cell carcinoma and tuberous sclerosis complex: a case report.

Authors:  Hye Sook Kim; Seung Tae Kim; Seok Ho Kang; Deuk Jae Sung; Chul Hwan Kim; Sang Won Shin; Yeul Hong Kim; Won Yong Cho; Kyong Hwa Park
Journal:  J Med Case Rep       Date:  2014-03-10

6.  Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: A systematic review and meta-analysis.

Authors:  Guang Yang; Lu Yang; Xiaofan Yang; Xiuyu Shi; Jing Wang; Yujie Liu; Jun Ju; Liping Zou
Journal:  Exp Ther Med       Date:  2014-11-27       Impact factor: 2.447

7.  mTOR Inhibitors in Tuberous Sclerosis Complex.

Authors:  Paolo Curatolo; Romina Moavero
Journal:  Curr Neuropharmacol       Date:  2012-12       Impact factor: 7.363

8.  Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration.

Authors:  Amos H P Loh; Rachel C Brennan; Walter H Lang; Robert J Hickey; Linda H Malkas; John A Sandoval
Journal:  Front Oncol       Date:  2013-04-23       Impact factor: 6.244

Review 9.  Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis.

Authors:  Teguh Haryo Sasongko; Nur Farrah Dila Ismail; Nik Mohamad Ariff Nik Abdul Malik; Z A M H Zabidi-Hussin
Journal:  Orphanet J Rare Dis       Date:  2015-08-12       Impact factor: 4.123

Review 10.  Is mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients?

Authors:  Samy L Habib; Noor Y Al-Obaidi; Maciej Nowacki; Katarzyna Pietkun; Barbara Zegarska; Tomasz Kloskowski; Wojciech Zegarski; Tomasz Drewa; Edward A Medina; Zhenze Zhao; Sitai Liang
Journal:  J Cancer       Date:  2016-07-21       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.